Search Results - Mark Cragg
- Showing 1 - 3 results of 3
-
1
Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways by Jennifer Edelmann, Arran D. Dokal, Emma Vilventhraraja, Karlheinz Holzmann, David Britton, Tetyana Klymenko, Hartmut Döhner, Mark Cragg, Andrejs Braun, Pedro Cutillas, John G. Gribben
Published in iScience (2021-02-01)Get full text
Article -
2
1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy by Monika Semmrich, Linda Mårtensson, Ingrid Teige, Björn Frendeus, Mathilda Kovacek, Petra Holmkvist, Carolin Svensson, Therese Blidberg, Andres McAllister, Marie Borggren, Ingrid Karlsson, Mark Cragg, Mimoza Bodén, Kirstie Cleary, Osman Dadas, Benjamin Duell, Jan Anders Nilsson, Stephen Beers, Sean Lim, Johan E Wallin
Published in Journal for ImmunoTherapy of Cancer (2023-11-01)Article -
3
757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab by Michael Chisamore, Jeffrey Yachnin, Ana Carneiro, Linda Mårtensson, Ingrid Teige, Björn Frendeus, Petra Holmkvist, Andres McAllister, Marie Borggren, Ingrid Karlsson, Mark Cragg, Lars Ny, Zsuzsanna Pápai, Kristoffer Staahl Rohrberg, Kirstie Cleary, Jan Anders Nilsson, Sean Lim, Johan E Wallin, Istvan Lang, Harriet Walter, Rikke H Lovendahl Eefsen, Edvard Abel, Robert Oldham, Susanne Gertsson
Published in Journal for ImmunoTherapy of Cancer (2023-11-01)Article